Top Research Papers on Ozempic

Ozempic (semaglutide) is a potent GLP-1 receptor agonist that effectively improves glycemic control and aids in weight reduction for patients with type 2 diabetes and obesity.

Phase III clinical trials of the SUSTAIN programme demonstrated both the efficacy and safety of semaglutide in patients with T2D treated by diet and exercise, oral antidiabetic agents or even insulin.

Abstract Background Glucagon-like peptide-1 (GLP-1) receptor agonists have gained popularity after clinical trials demonstrated their weight-loss potential. The term “Ozempic® face” has been coined to describe the exaggerated volume loss from semaglutide therapy, resulting in advanced facial aging. Objectives The authors of this study aim to review plastic surgery publications discussing GLP-1 receptor agonists and characterize the public's perception of the effect of these medications on weight loss. Methods A systematic review of the PubMed database was conducted to identify articles discuss...

NICE guidance recommends that in adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team.

The use of semaglutide (Ozempic®) in Denmark has increased dramatically, and although not approved for weight loss without T2D, one-third of new users in 2022 did not have T2D.

This study examines the weight-related discourses in holiday advertising for Ozempic, a prescription drug originally developed for diabetes management but now widely marketed for weight loss, and highlights how these marketing strategies mobilize biopower, construct self-surveillance as normative, and contribute to the commodification of health.

This term is a new purported side effect, used to describe the rapid facial weight loss leaving a distorted facial appearance, that challenges the healthcare team to discern whether a new adverse effect is a novel or a natural consequence of rapid weight loss.

As the use of GLP-1 agonists for weight loss becomes more prevalent, plastic surgeons must be prepared for the downstream implications and increased awareness, understanding, and further scientific studies led by plastic surgeons will help deliver the safest possible patient outcomes.

Dear Editor, I am writing to highlight a noteworthy and developing area of research regarding the potential impact of Ozempic or Semaglutide on the reproductive health of women suffering from polycystic ovarian syndrome (PCOS). Known as a chronic condition which causes hormonal imbalances in women of reproductive age, PCOS has a staggering prevalence of 52% amongst Pakistani women.1 Ozempic, widely recognized for its efficacy in managing type 2 diabetes and promoting weight loss, has recently been observed to potentially influence reproductive health, particularly by enhancing fertility in wom...

The Ozempic (semaglutide) has good results in helping to lose weight in obese patients, despite being developed for the treatment of patients with type 2 diabetes mellitus, the results for obesity were positive and this factor has not been proven in humans and is considered a disadvantage.

Semaglutide can be added to existing treatment to improve glycemic control and induce weight loss and may also protect against cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease.

Background: Previous randomised controlled trials have observed individual differences in response to Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) according to baseline characteristics such as glycated haemoglobin (HbA1c) and weight. The Association of British Clinical Diabetologists (ABCD) launched a nationwide UK audit in January 2019 to assess the clinical utility, efficacy and safety of injectable semaglutide in routine practice. The aim of this analysis was to investigate associations between baseline characteristics and HbA1c and weight reductions with semaglutide in real-world use...

Introdução: A obesidade é uma doença crônica proveniente de um distúrbio metabólico funcional do organismo, caracterizada pelo acúmulo excessivo de gordura que acarreta diversos efeitos prejudiciais à saúde. O Ozempic® vem atualmente ganhando espaço, sendo muito utilizado de forma off-label no tratamento da obesidade. Objetivo: Analisar a eficácia e segurança do uso da semaglutida (Ozempic®) como abordagem terapêutica no tratamento da obesidade. Metodologia: O estudo trata-se de uma revisão bibliográfica, em que se seguiu o método PRISMA, utilizando as bases de dados BVS, Scielo, Pubmed e Peri...

A case of a 46-year-old patient who presented with significant facial edema 3 months after lip and infraorbital filling with hyaluronic acid, resistant to medication, which appeared and worsened after starting to use Ozempic for weight loss is presented.

Despite the prevalence of gastrointestinal symptoms, semaglutide remains an efficacious option for managing diabetes and obesity and the detailed characterization of adverse events underscores the importance of monitoring and managing these effects in clinical practice.

In patients with T2D, HDG1901 was equivalent to reference semaglutide with respect to the mean changes from baseline in HbA1c at 32 weeks and offers an option for the treatment of T2D.

From disrupted epidermal barriers to diseases such as psoriasis and hidradenitis suppurativa, it further explores how licensed cosmetologists emerge as health advocates and examines semaglutide's mechanism, efficacy, and unintended consequences of popularity.

This case report underscores the adverse mood changes possibly linked to semaglutide and the need for further study in this area.

This research note explores the potential of Semaglutide, a GLP-1 agonist similar to Ozempic, as a preventive anti-cancer agent and touches upon the promising relationship between GLP-1 receptor agonists and cancer treatment.

Non-diabetic males with a prescription of semaglutide have a significantly higher risk of developing ED and testosterone deficiency, and these rates were surprised that these rates were so much higher than those not receiving semaglutide as it was expected that weight loss drugs would improve erectile function.